e-learning
resources
ERJ
2016
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Docosahexaenoic acid causes rapid pulmonary arterial relaxation via KCa channel-mediated hyperpolarisation in pulmonary hypertension
Nagaraj Chandran, Tang Bi, Nagy Bence M., Papp Rita, Jain Pritesh P., Marsh Leigh M., Meredith Andrea L., Ghanim Bahil, Klepetko Walter, Kwapiszewska Grazyna, Weir E. Kenneth, Olschewski Horst, Olschewski Andrea
Source:
Eur Respir J 2016; 48: 1127-1136
Journal Issue:
October
Disease area:
Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Nagaraj Chandran, Tang Bi, Nagy Bence M., Papp Rita, Jain Pritesh P., Marsh Leigh M., Meredith Andrea L., Ghanim Bahil, Klepetko Walter, Kwapiszewska Grazyna, Weir E. Kenneth, Olschewski Horst, Olschewski Andrea. Docosahexaenoic acid causes rapid pulmonary arterial relaxation via KCa channel-mediated hyperpolarisation in pulmonary hypertension. Eur Respir J 2016; 48: 1127-1136
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
The definition of pulmonary hypertension: history, practical implications and current controversies
Should we screen for hereditary pulmonary hypertension?
Patient with ankylosing spondylitis and pulmonary hypertension
Related content which might interest you:
Potassium channels in pulmonary arterial hypertension
Source: Eur Respir J 2015; 46: 1167-1177
Year: 2015
SUR1/Kir6.2 potassium channel a new actor involved in pulmonary arterial hypertension
Source: Virtual Congress 2020 – Pathophysiology of pulmonary hypertension
Year: 2020
Role of NO pathway, calcium and potassium channels in the peripheral pulmonary vascular tone in dogs
Source: Eur Respir J 2001; 17: 20-26
Year: 2001
Ca
2+
-activated K
+
channel openers cause epithelium and endothelium-dependent relaxation in pulmonary tissue
Source: Annual Congress 2008 - Pulmonary vascular biology
Year: 2008
Loss of response to calcium channel blockers after long-term follow up in idiopathic pulmonary arterial hypertension
Source: Virtual Congress 2020 – Epidemiology and treatment of pulmonary arterial hypertension
Year: 2020
Uric acid causes excessive pulmonary arterial smooth muscle cell proliferation via URATv1 upregulation in pulmonary arterial hypertension
Source: International Congress 2016 – The nature of pulmonary hypertension
Year: 2016
Targeting TMEM16A to reverse vasoconstriction and remodelling in idiopathic pulmonary arterial hypertension
Source: Eur Respir J, 53 (6) 1800965; 10.1183/13993003.00965-2018
Year: 2019
KCNK3 channel inactivation leads to pulmonary vascular alterations in rat
Source: International Congress 2018 – Pathobiology of pulmonary hypertension
Year: 2018
Iloprost for pulmonary vasodilator testing in idiopathic pulmonary arterial hypertension
Source: Eur Respir J 2009; 33: 1354-1360
Year: 2009
Stable prostacyclin analogues treprostinil and iloprost activates K
Ca
and two-pore domain TASK-1 channels in human pulmonary artery smooth muscle cells
Source: Annual Congress 2008 - Pathophysiology of pulmonary hypertension
Year: 2008
Dehydroepiandrosterone sulphate reduces chronic hypoxic pulmonary hypertension in rats
Source: Eur Respir J 2003; 21: 862-865
Year: 2003
The potential effects of pregnancy in a patient with idiopathic pulmonary arterial hypertension responding to calcium channel blockade
Source: Eur Respir J, 50 (6) 1701141; 10.1183/13993003.01141-2017
Year: 2017
Increased hyaluronic acid content in idiopathic pulmonary arterial hypertension
Source: Eur Respir J 2008; 32: 1504-1512
Year: 2008
TRAM-34 ameliorates hypoxia-induced pulmonary arterial hypertension in rats
Source: Annual Congress 2013 –Pulmonary circulation: animal models and experimental treatments
Year: 2013
NMDA receptor activation promotes vascular remodeling and pulmonary arterial hypertension
Source: International Congress 2018 – Pathobiology of pulmonary hypertension
Year: 2018
Involvement of CFTR in the pathogenesis of pulmonary arterial hypertension
Source: Eur Respir J, 58 (5) 2000653; 10.1183/13993003.00653-2020
Year: 2021
Effects of suramin on cardiopulmonary capacity and pulmonary venous contraction in pulmonary arterial hypertension
Source: International Congress 2018 – Pulmonary hypertension in lung diseases and the role of the right ventricle
Year: 2018
Kv1.5 channels and endothelium-dependent relaxation are downregulated by miR-1 in rat pulmonary arteries.
Source: International Congress 2018 – Experimental research in pulmonary hypertension
Year: 2018
Spermine promotes pulmonary vascular remodelling and its synthase is a therapeutic target for pulmonary arterial hypertension
Source: Eur Respir J, 56 (5) 2000522; 10.1183/13993003.00522-2020
Year: 2020
MnTBAP reduces pulmonary vascular remodeling in experimental pulmonary arterial hypertension
Source: International Congress 2019 – Pulmonary hypertension: novelties from the bench
Year: 2019
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept